Cargando…
Excluding Participants With Mycobacteria Infections From Clinical Trials: A Critical Consideration in Evaluating the Efficacy of BCG Against COVID-19
In the context of the coronavirus disease 2019 (COVID-19) pandemic, Bacillus Calmette-Guérin (BCG), a tuberculosis (TB) vaccine, has been investigated for its potential to prevent COVID-19 with conflicting outcomes. Currently, over 50 clinical trials have been conducted to assess the effectiveness o...
Autores principales: | Gong, Wenping, Du, Jingli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615642/ https://www.ncbi.nlm.nih.gov/pubmed/37904656 http://dx.doi.org/10.3346/jkms.2023.38.e343 |
Ejemplares similares
-
Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19
por: Du, Jingli, et al.
Publicado: (2023) -
Exploring BCG vaccination as a novel approach to prevent recurrent herpes labialis
por: Gong, Wenping, et al.
Publicado: (2023) -
Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis()
por: Poyntz, Hazel C., et al.
Publicado: (2014) -
IV BCG Vaccination and Aerosol BCG Revaccination Induce Mycobacteria-Responsive γδ T Cells Associated with Protective Efficacy against M. tb Challenge
por: Morrison, Alexandra L., et al.
Publicado: (2023) -
Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)